Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019025440) COMBINATION OF ATR KINASE INHIBITORS AND PD-1/PD-L1 INHIBITORS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/025440 International Application No.: PCT/EP2018/070729
Publication Date: 07.02.2019 International Filing Date: 31.07.2018
IPC:
A61K 45/06 (2006.01) ,C07D 471/04 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45
Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
471
Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
02
in which the condensed system contains two hetero rings
04
Ortho-condensed systems
Applicants:
BAYER PHARMA AKTIENGESELLSCHAFT [DE/DE]; Müllerstr. 178 13353 Berlin, DE
BAYER AKTIENGESELLSCHAFT [DE/DE]; Kaiser-Wilhelm-Allee 1 51373 Leverkusen, DE
Inventors:
WENGNER, Antje, Margret; DE
Agent:
BIP PATENTS; Alfred-Nobel-Str. 10 40789 Monheim am Rhein NRW, DE
Priority Data:
17184950.804.08.2017EP
Title (EN) COMBINATION OF ATR KINASE INHIBITORS AND PD-1/PD-L1 INHIBITORS
(FR) COMBINAISON D'INHIBITEURS DE KINASE ATR ET D'INHIBITEURS DE PD-1/PD-L1
Abstract:
(EN) The present invention covers combinations of at least two components, component A and component B, comprising component A being an inhibitor of ATR kinase, particularly an inhibitor of ATR kinase selected from VX-803, VX-970, AZD-6738, a compound of general formula (I) described herein, a compound of general formula (lb) described herein and Compound A described infra, and component B being a PD-1/PD-L1 inhibitor described herein. Another aspect of the present invention covers the use of such combinations as described herein for the preparation of a medicament for the treatment or prophylaxis of a disease, particurlarly for the treatment of a hyper-proliferative disease.
(FR) La présente invention couvre des combinaisons d'au moins deux constituants, le constituant A et le constituant B, comprenant le constituant A qui est un inhibiteur de la kinase ATR , en particulier un inhibiteur de la kinase ATR sélectionné parmi VX-803, VX-970, AZD-6738, un composé de formule générale (I) décrit ci-dessous, un composé de formule générale (Ib) décrit ci-dessous et le composé A décrit ci-dessous et le constituant B qui est un inhibiteur de PD-1/PD-L1 décrit ci-dessous. Un autre aspect de la présente invention couvre l’utilisation des combinaisons telles que décrites dans la description pour la préparation d’un médicament destiné au traitement ou à la prophylaxie d’une maladie, en particulier au traitement d'une maladie hyperproliférative.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)